JP2016512201A - 急性腎障害の治療方法 - Google Patents

急性腎障害の治療方法 Download PDF

Info

Publication number
JP2016512201A
JP2016512201A JP2015561753A JP2015561753A JP2016512201A JP 2016512201 A JP2016512201 A JP 2016512201A JP 2015561753 A JP2015561753 A JP 2015561753A JP 2015561753 A JP2015561753 A JP 2015561753A JP 2016512201 A JP2016512201 A JP 2016512201A
Authority
JP
Japan
Prior art keywords
injury
induced
subject
ischemia
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015561753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512201A5 (enExample
Inventor
ゼーガー，リチャード・エイ
アンドレス，デニ
Original Assignee
アッヴィ・インコーポレイテッド
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・インコーポレイテッド, フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター filed Critical アッヴィ・インコーポレイテッド
Publication of JP2016512201A publication Critical patent/JP2016512201A/ja
Publication of JP2016512201A5 publication Critical patent/JP2016512201A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015561753A 2013-03-08 2014-03-10 急性腎障害の治療方法 Pending JP2016512201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
US61/775,174 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (2)

Publication Number Publication Date
JP2016512201A true JP2016512201A (ja) 2016-04-25
JP2016512201A5 JP2016512201A5 (enExample) 2017-04-13

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561753A Pending JP2016512201A (ja) 2013-03-08 2014-03-10 急性腎障害の治療方法

Country Status (10)

Country Link
US (1) US20160015701A1 (enExample)
EP (1) EP2964671A4 (enExample)
JP (1) JP2016512201A (enExample)
CN (1) CN105324395A (enExample)
AU (1) AU2014225320A1 (enExample)
BR (1) BR112015020788A2 (enExample)
CA (1) CA2901922A1 (enExample)
HK (1) HK1220209A1 (enExample)
MX (1) MX2015011730A (enExample)
WO (1) WO2014138738A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190097708A (ko) * 2018-02-13 2019-08-21 서울대학교병원 체세포 복제 효율 증진용 조성물
JP2019533660A (ja) * 2016-10-05 2019-11-21 ミトブリッジ，インコーポレーテッド 急性腎障害を処置する方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014259961A1 (en) 2013-04-30 2015-11-05 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
AU2020379649A1 (en) * 2019-11-06 2022-05-26 Mannin Research Inc. Inhibition of the VE-PTP phosphatase protects the kidney from ischemia-reperfusion injury
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
JP2023521169A (ja) * 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501778A (ja) * 1992-09-22 1996-02-27 ジェネンテク，インコーポレイテッド 急性腎不全の予防方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005104702A2 (en) * 2004-04-23 2005-11-10 Renal Diagnostic, Inc. An automated non- invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501778A (ja) * 1992-09-22 1996-02-27 ジェネンテク，インコーポレイテッド 急性腎不全の予防方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN. J. PHARMACOL., vol. 82, JPN6017043735, 2000, pages 307 - 316, ISSN: 0003822886 *
MOL. MED., vol. Vol.14(7-8), JPN6017043736, 2008, pages 502 - 516, ISSN: 0003822887 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533660A (ja) * 2016-10-05 2019-11-21 ミトブリッジ，インコーポレーテッド 急性腎障害を処置する方法
JP7065839B2 (ja) 2016-10-05 2022-05-12 ミトブリッジ，インコーポレーテッド 急性腎障害を処置する方法
KR20190097708A (ko) * 2018-02-13 2019-08-21 서울대학교병원 체세포 복제 효율 증진용 조성물
KR102177349B1 (ko) 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물

Also Published As

Publication number Publication date
EP2964671A4 (en) 2016-08-31
CN105324395A (zh) 2016-02-10
EP2964671A1 (en) 2016-01-13
WO2014138738A1 (en) 2014-09-12
HK1220209A1 (zh) 2017-04-28
MX2015011730A (es) 2016-04-04
BR112015020788A2 (pt) 2017-10-10
CA2901922A1 (en) 2014-09-12
WO2014138738A8 (en) 2015-12-30
US20160015701A1 (en) 2016-01-21
AU2014225320A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
JP2016512201A (ja) 急性腎障害の治療方法
Mehrotra et al. Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury
Katagiri et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition
Calvin et al. Contrast-induced acute kidney injury and diabetic nephropathy
JP5392980B2 (ja) 早発型の腎尿細管細胞障害を検出するための方法およびキット
JP6822412B2 (ja) 妊娠高血圧腎症のための診断アッセイ及び治療
Maggi et al. Novel antiretroviral drugs and renal function monitoring of HIV patients
Naka et al. Hsp70 regulates the doxorubicin-mediated heart failure in Hsp70-transgenic mice
JP2020073531A (ja) Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
Frascà et al. Renal cancer in kidney transplanted patients
JP2014503499A (ja) 低酸素状態に基づく治療に適した被験体の事前選択
US20140088191A1 (en) Inhibition of Renal Fibrosis
Baines et al. Antiviral inflammation during early pregnancy reduces placental and fetal growth trajectories
US20220143017A1 (en) Pharmaceutical composition for preventing and treating diabetic nephropaphy including adenosine derivative
Ogura et al. Potential amelioration of upregulated renal HIF-1alpha–endothelin-1 system by landiolol hydrochloride in a rat model of endotoxemia
Gustafsson et al. Eosinophil activation in systemic sclerosis
Kalimeris et al. Mannitol and renal dysfunction after endovascular aortic aneurysm repair procedures: a randomized trial
JP2015504088A (ja) 肝疾患の治療
Deng et al. Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats
CN107405403A (zh) 用于治疗纤维化的塞尼克韦罗
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
KR20230107866A (ko) Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법
Vijay et al. Autosomal dominant polycystic kidney disease: a comprehensive review
McDonald et al. Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy
Prasad et al. Spectrum of renal histopathologic lesions in patients with nonlupus rheumatologic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180626